Results 131 to 140 of about 190,081 (230)

The ASCO Provider Utilization File (ASCO PUF): A Closer Look [PDF]

Journal of Oncology Practice, 2016
openaire   +2 more sources

Efecto de la sensibilidad al asco sobre los síntomas hipocondríacos: un estudio prospectivo

, 2013
En este artículo investigamos la asociación entre la sensibilidad al asco y los síntomas de hipocondría y ansiedad hacia la salud. Los participantes cumplimentaron la Escala Multi­dimensional de Sensibilidad al Asco (EMA; Sandín et al., 2013), la Illness
Sandín, Bonifacio, Valiente García, Rosa María, Santed Germán, Miguel Angel, Pineda, David, Olmedo, Margarita, Chorot, Paloma   +5 more
core  

PD-(L)1×VEGF bispecific antibodies in solid tumors: clinical trial updates from ASCO 2026. [PDF]

J Hematol Oncol
Wang Z, Guo C, Yuan X, Guo Q, Zhang R, Chen Z.   +5 more
europepmc   +1 more source

Harmonizing biomarker testing in NSCLC: The critical role of cytopathology in delivering comprehensive biomarker testing for patients with NSCLC. [PDF]

Cancer Cytopathol
Roy-Chowdhuri S, Mani H.
europepmc   +1 more source

Asco's Stations of the Cross

, 1971
full ...
ASCO
core  

HER2 Expression in Squamous Cell Carcinoma of the Vulva: A Systematic Review and Meta-Analysis. [PDF]

Cancers (Basel)
Farias Müller NL, Sibani MA, Ayoub Y, Ayoub M, Pullattayil AK, Tavangar F, Plotkin A, George S, Jerzak KJ, Mackay H, Chehade R.   +10 more
europepmc   +1 more source

The KRAS targeting revolution in metastatic pancreatic cancer: insights from the landmark RASolute-302 trial and emerging allele-specific strategies at ASCO 2026. [PDF]

J Hematol Oncol
Pillozzi S, Giommoni E, Petroni G, Rossini D, Lavacchi D, Brugia M, Galli A, Antonuzzo L.   +7 more
europepmc   +1 more source

Ten-Year Parapapillary Gamma Zone Expansion and Axial Elongation in High Myopia Based on SS-OCT Imaging. [PDF]

Invest Ophthalmol Vis Sci
Wu Y, Liang Y, Huang Z, Li Z, Hong H, Yan B, Shang M, Xue Y, Tan S, Yu H, He M, Wang W.   +11 more
europepmc   +1 more source

Relapse rate after adjuvant trastuzumab in the northeast of Italy: Preliminary data from a multicenter observational study in a clinical setting. J Clin Oncol 30, 2012 (suppl; abstr 586)

, 2012
Background: Relapse Rate (RR) after Adjuvant Trastuzumab (AT) reported in clinical trials is between 15 and 21%. Information on RR and clinical behaviour of HER2-POS metastatic disease after AT outside clinical trials is limited.
AM Molino, on Behalf of Italian North East HER2 STUDY GROUP, MUSTACCHI, GIORGIO, E. Fiorio   +3 more
core  

Role of Sentinel Node Surgery in Identifying Candidates for Adjuvant CDK4/6 Inhibitors: Implications of Choosing Wisely and ASCO Omission Criteria. [PDF]

Ann Surg Oncol
Williams AD, Lyons W, Taylor LB, Chang C, Jain A, McShane M, Aggon AA, So A, Winn J, Bleicher RJ.   +9 more
europepmc   +1 more source